TCRX (TScan Therapeutics) Institutional Ownership: 48.65% (As of Sep. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TCRX TScan Therapeutics Inc TCRX
44 GF Score
Price $0.73
GF Value $1.32
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is TScan Therapeutics Institutional Ownership?

TScan Therapeutics TCRX -3.15% 44 Institutional Ownership is 48.65% as of Sep. 01, 2026. GuruFocus rates TCRX with a GF Score™ of 44/100 and a GF Value™ of $1.32 (Possible Value Trap). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TScan Therapeutics's institutional ownership is 48.65%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TScan Therapeutics's Insider Ownership is 1.98%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TScan Therapeutics's Float Percentage Of Total Shares Outstanding is 69.63%.

TScan Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for TScan Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TScan Therapeutics Institutional Ownership Chart

TScan Therapeutics Historical Data

The historical data trend for TScan Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 10.21 9.62 8.55 8.51 8.17 7.64 6.77 6.18 5.96 9.19
TCRX
44GF Score
TScan Therapeutics Inc TCRX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TScan Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 48.65% mean?
TScan Therapeutics (TCRX) has a Institutional Ownership of 48.65% as of Sep. 01, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on TScan Therapeutics and its competitors.
Is TScan Therapeutics' Institutional Ownership too high?
TScan Therapeutics' current Institutional Ownership is 48.65%. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' Institutional Ownership compare to MCRB and HYPD?
TScan Therapeutics' Institutional Ownership of 48.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on TScan Therapeutics and its competitors. TScan Therapeutics's current Institutional Ownership is 48.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.73 — trading 44.7% below its estimated fair value. The current Institutional Ownership is 48.65%. TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current Institutional Ownership is 48.65% as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TScan Therapeutics (TCRX) Overvalued in 2026?

Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued. The current stock price of $0.73 is trading 44.7% below its estimated GF Value™ of $1.32. GuruFocus considers TScan Therapeutics to be Possible Value Trap.

Key valuation signals for TCRX:

  • Institutional Ownership: 48.65%
  • GF Value™: $1.32 vs. price of $0.73 (44.7% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TScan Therapeutics Business Description

Address 830 Winter Street, Waltham, MA, USA, 02451
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score

Get the complete analysis for TCRX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price
$1.32
GF Value